InterVenn
InterVenn BioSciences Hits Commercial Phase, Launches Test for Immunotherapy Response in Melanoma
Premium
At the ASCO meeting this week, the firm will present validation data on the test, which predicts response to immune checkpoint inhibitors in advanced melanoma.